BioSpace News Archive

Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX) a biopharmaceutical company and the leader in NOX therapies, announces today further progress in two investigator-initiated Phase II trials of setanaxib in diabetic kidney disease (DKD) and idiopathic pulmonary fibrosis (IPF).

Until December 8, Aeroplan Miles donated to the Air Canada Foundation will be matched to help transport sick children for medical care they need away from home

Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that Proteostasis management will present at the Piper Jaffray 31st Annual Healthcare Conference on Thursday

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced preliminary results from patients with transfusion-dependent (TD) beta-thalassemia in the ongoing TRANSCEND Phase 2 open-label study of PTG-300.

Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB: ASPCF) announced today that Edward Gudaitis, President and Chief Executive Officer, will present an overview of the company at the 12th Annual LD Micro Main Event investor conference at 3:40 pm Pacific Time on Tuesday December 10, 2019 at the Luxe Sunset Boulevard Hotel in Los Angeles California.

Rapid Expansion of recombinant Spider Silk production on track to grow Operations and yield Fibers for first significant fabric production run

Novel Organ-Selective Pan-JAK Inhibitor Specifically Designed to Target Airway Inflammation in the Lung With Minimal Systemic Exposure Allergen Challenge Study Expected to Provide Key Insights to Support Ongoing Clinical Development of TD-8236

First IND clearance of a clinical candidate derived from Atreca’s differentiated drug discovery platform

Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, announced that the first patient has been dosed in its Phase 2a vitiligo clinical trial for topical cerdulatinib.

Patent Underpins CNTX-4975 Formulation Technology and Provides Intellectual Property Protection into 2037